WASHINGTON, DC–(Marketwire -06/05/12)- The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine community, today announced the full agenda for the Clinical Outlooks for Regenerative Medicine meeting. The event will take place on June 19, 2012 at The Starr Center, Schepens Eye Research Institute, 185 Cambridge Street, Boston, MA.
As regenerative medicine and cell therapy products advance further in clinical studies toward gaining approval, it is important to understand how these products will be administered and how they will perform clinically. This meeting, which was organized jointly by ARM and the Harvard Stem Cell Institute, will explore the clinical status for certain key disease areas from the perspective of clinicians, patient groups and leading regenerative medicine companies. The full agenda is as follows:
Brock Reeve, Harvard Stem Cell Institute
Gil Van Bokkelen, Ph.D., ARM; Athersys, Inc.
Ellen Feigal, M.D., California Institute for Regenerative Medicine
Gary Rabin, Advanced Cell Technology
Jane Sowden, Ph.D., University College London Institute of Child Health
Michael Young, Ph.D., Schepens Eye Research Institute; Harvard Medical School
Peter Lomedico, Ph.D., JDRF
Jason Gaglia, M.D., M.M.Sc., Joslin Diabetes Center; Harvard Medical School
Bernhard Hering, M.D., Schulze Diabetes Institute; University of Minnesota
Allan Robins, Ph.D., ViaCyte
Mark Zimmerman, Ph.D., BetaLogics, a division of Janssen Pharmaceutical Companies of Johnson & Johnson
George Daley, M.D., Ph.D., HHMI/Children’s Hospital Boston, Harvard Medical School, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Stem Cell Institute and Manton Center for Orphan Disease Research
Amy Comstock Rick, J.D., Parkinson’s Action Network
James Berry, M.D., Ph.D., Massachusetts General Hospital; Harvard Medical School
Stephen Huhn, M.D., F.A.C.S., F.A.A.P., StemCells, Inc.
Mark Noble, Ph.D., University of Rochester Medical Center
Edward Wirth, M.D., Ph.D., InVivo Therapeutics
Richard Lee, M.D., Harvard Medical School; Harvard Stem Cell Institute; Brigham and Women’s Hospital
Marc Penn, M.D., Ph.D., F.A.C.C., Summa Cardiovascular Institute; Summa Akron City Hospital; Northeast Ohio Medical University
Jonathan Sackner-Bernstein, M.D., F.A.C.C., NeoStem
Michael Schuster, Mesoblast
Skip Irving, Health Advances
Dolores Baksh, Ph.D., Organogenesis
Charles Hart, Ph.D., Advanced BioHealing, a Shire Company
Ira Herman, Ph.D., Tufts University School of Medicine
Robert Kirsner, M.D., Ph.D., University of Miami School of Medicine
To learn more and to register for the conference, please visit https://alliancerm.wufoo.com/forms/clinical-outlooks-for-regenerative-medicine/. Complimentary registration is available for credentialed members of the media and HSCI affiliated clinicians and researchers.
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, click here.
The Harvard Stem Cell Institute (HSCI) is a scientific collaborative established to investigate the complex biology and therapeutic potential of stem cells. With over 200 faculty members at Harvard and its 11 affiliated hospitals, HSCI supports cutting-edge science through sponsoring research projects, operating core facilities, managing events and offering training opportunities.